I-Afatinib CAS 439081-18-2 Purity >99.5% (HPLC) Factory

Incazelo emfushane:

Igama Lekhemikhali: Afatinib

Amazwi afanayo: BIBW2992

I-CAS: 439081-18-2

Ubumsulwa: >99.5% (HPLC)

Ukubukeka: I-Off-White Powder

E-Mail: alvin@ruifuchem.com


Imininingwane Yomkhiqizo

Imikhiqizo Ehlobene

Omaka bomkhiqizo

Incazelo:

Chemical Properties:

Igama Lekhemikhali Afatinib
Omqondofana BIBW2992;I-BIBW-2992;BIBW2992 Isizinda samahhala;I-Tomtovok;(S,E)-N-(4-(3-Chloro-4-Fluorophenylamino)-7-(Tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(Dimethylamino)kodwa-2-Enamide
Inombolo ye-CAS 439081-18-2
Inombolo yeCAT I-RF-PI2033
Isimo Sesitoko Esitokweni, Isikali Sokukhiqiza Sifinyelela Kumathani
I-Molecular Formula I-C24H25ClFN5O3
Isisindo samangqamuzana 485.94
Ukuncibilika I-Soluble ku-DMSO
Ukuminyana 1.380
Ibhrendi I-Ruifu Chemical

Imininingwane:

Into Imininingwane
Ukubukeka I-Off-White Powder
Ukuhlonza I-HPLC, NMR
Ukuhlanzeka / Indlela Yokuhlaziya >99.5% (HPLC)
I-Melting Point 100.0~102.0℃
Ukulahlekelwa Ekumisweni <0.50%
Izinsalela ekushiseni <0.20%
Ukungcola Okuphelele <0.50%
Izinsimbi Ezisindayo ≤20ppm
I-NMR Spectrum Ivumelana Nesakhiwo
Izinga Lokuhlola I-Enterprise Standard
I-Shelf Life Izinyanga Ezingu-24 Uma Zigcinwe Ngokufanelekile
Ukusetshenziswa I-API;I-Afatinib;I-Afatinib Dimaleate;I-NSCLC

Iphakheji nesitoreji:

Iphakheji: Ibhodlela, isikhwama se-Aluminium foil, 25kg/Cardboard Drum, noma ngokwemfuneko yekhasimende

Isimo Sesitoreji:Gcina ezitsheni ezivaliwe endaweni epholile neyomile;Vikela ekukhanyeni nakumswakama

Izinzuzo:

1

I-FAQ:

Isicelo:

I-Afatinib, eyaziwa nangokuthi i-BIW-2992, (i-CAS: 439081-18-2) isizukulwane sesibili esinamandla futhi esingenakuhlehliswa inhibitor ye-epidermal growth factor receptor (EGFR) kanye ne-human epidermal growth factor receptor 2 (HER2) i-tyrosine kinase, ithuthukiswe ngu-Boehringer Ingelheim, eJalimane.Iyakwazi ukuvimbela ngendlela engenakuhlehliswa umsebenzi we-tyrosine kinase ngokubhekana nokusabela kukaMichael neqembu le-thiol le-cysteine ​​​​indawo engu-797 ye-EGFR.Ngomhla ziyi-12 kuJulayi, 2013, yaba umuthi omusha wokulwa nomdlavuza wamaphaphu wamangqamuzana amancane ogunyazwe yi-US FDA ngaphansi kwegama lokuhweba elithi Gilotrif.Lesi sidakamizwa ithebhulethi.Isetshenziselwa ukwelapha iziguli ezitholwe zinomdlavuza we-metastatic non-small cell lung cancer (NSCLC) ngokulahleka kwe-19th exon noma ukuguqulwa kwe-L858R ku-exon yama-21 ye-tumor epidermal growth factor receptor (EGFR) eqinisekiswe kusetshenziswa ikhithi egunyaziwe. nge-FDA.Umuthi uyasebenza futhi ekwelapheni iziguli ezine-HER2 ezinomdlavuza webele othuthukile.I-Afatinib ingeyesigaba sezidakamizwa ezaziwa ngokuthi i-tyrosine kinase inhibitors.I-Tyrosine kinase inhibitors iklanyelwe ukuvimba isenzo se-enzyme ethile ebizwa ngokuthi i-tyrosine kinase.Le enzyme idlala indima enkulu emsebenzini wamaseli, futhi iyasebenza ekukhuthazeni ukukhula nokuqhubeka kwesimila.I-Afatinib isebenza ukuvimbela ukusebenza kwezinhlobo ezimbili ze-tyrosine kinases: i-epidermal growth factor receptor (EGFR) kanye ne-Her2, "evezwa ngokweqile" izinhlobo eziningana zomdlavuza.Ngokuvimbela ukusebenza kwalawa ma-tyrosine kinases, i-Afatinib ingase ivimbele amangqamuzana omdlavuza ukuba ahlukane futhi akhule.

Bhala umyalezo wakho lapha futhi usithumelele wona